The success of any in vivo phage display project depends on two critical factors: a robust technology platform and the selection of the right animal model. This advanced in vivo screening method offers many clear benefits for your discovery project:
At Creative Biolabs, we have built a world-class platform specifically for this purpose. We combine advanced molecular biology with expert knowledge of animal physiology to create a screening environment that delivers relevant and reliable results. While our primary Antibody Screening with In Vivo Phage Display Service gives a broad overview of the applications, this in vivo phage display screening platform explores the technical details of how we achieve such great results. Here, we will dive into the core of our platform and explain how we use different animal models to find the specific, high-performing antibodies your research demands.
Our platform is more than just a single method; it is a complete system of advanced tools and strategies designed to maximize the chances of discovering your ideal antibody.
At Creative Biolabs, we have designed a comprehensive and meticulous workflow to ensure your project's success. We work with you at every stage, from planning to validation.
Fig.1 The workflow for in vivo phage display.1
Every great project starts with a great plan. Our expert scientists will meet with you to understand your goals. We will discuss your target, what you want the antibody to do, and the best disease model for your research. This first step ensures that the project is designed perfectly for your needs.
We offer several types of high-quality phage display libraries:
We will help you choose the best library and the most suitable animal model to give your project the highest chance of success.
This is the core of the discovery process. After we inject the phage library, we perform several rounds of selection to identify the most effective antibodies. With each round, we can make the selection conditions more difficult (this is called increasing the "stringency"). This helps us find the antibodies that bind the tightest and are the most specific for your target.
After the panning rounds, we utilize a powerful technology called NGS. Instead of just selecting a few of the best clones, NGS enables us to analyze the DNA of the entire pool of successful phages. This provides us with a comprehensive view of all the promising antibody candidates. With this information, you can choose from a wider variety of excellent antibodies to move forward with.
Finding a good antibody "hit" is just the beginning. We offer a full range of services to test and validate your lead candidates. We can measure how tightly they bind to their target, reformat them into full-length antibodies (like IgG), and test how they function in cell-based assays. We provide you with a fully characterized antibody that is ready for the next stage of your research.
Selecting the correct animal model is the most critical decision in an in vivo panning experiment. The model must accurately represent the disease or tissue you are targeting. Our platform is flexible and can be used with a wide range of well-established animal models.
For many projects, standard mouse or rat models are the perfect choice. They are excellent for general biodistribution studies, discovering antibodies that can cross the blood-brain barrier (BBB), and for initial screenings against healthy tissues. We have experience with various strains, including Balb/c and C57BL/6 mice, to best suit the needs of your project.
To study human cancers, we often use special immunocompromised animal models, such as nude or SCID mice. These mice have a weakened immune system, which allows them to accept human tumor grafts (xenografts) without rejecting them. This makes them essential for our tumor-homing antibody discovery service, as we can screen for antibodies directly against a human tumor growing in a living system.
For many non-cancer diseases, we use special models that are designed to mimic the human condition. For example, we can use rabbit or mouse models of atherosclerosis to find antibodies that target plaques in arteries. Using a model that closely resembles the human disease leads to the discovery of more clinically relevant antibodies.
A successful in vivo antibody screening requires careful planning and control. Our team of experts precisely optimizes several key factors to ensure the best possible outcome.
Our in vivo phage display platform is built on a foundation of deep scientific knowledge and a commitment to innovation.
to discuss how our advanced platform and expert team can help move your research forward.
What is the primary advantage of in vivo over in vitro phage display?
The single greatest advantage is physiological relevance. In vivo antibody screening selects candidates in a living system, meaning it simultaneously screens for high-affinity binding to native targets, bioavailability, circulatory stability, and tissue accessibility—parameters that are completely overlooked in in vitro methods.
What antibody formats can be screened using this platform?
Our platform is compatible with all major antibody fragment formats used in phage display, including scFv (single-chain variable fragment), Fab (fragment, antigen-binding), and VHH (single-domain antibodies). The choice of format depends on the specific goals of your project, such as desired size, stability, and valency.
How are animal welfare concerns addressed?
Creative Biolabs is deeply committed to the highest standards of animal welfare and ethical conduct, adhering to all relevant national and international guidelines. We follow the principles of the 3Rs (Replacement, Reduction, and Refinement). In vivo phage display aligns with the "Refinement" and "Reduction" principles by selecting the most promising candidates early on, thereby reducing the number of animals required for downstream efficacy and safety testing. All procedures are meticulously planned to minimize animal stress and are approved by our institutional animal care and use committee.
Can this technology be used to find an antibody for a target that has never been identified before?
Absolutely. This is one of the most exciting applications of in vivo biopanning for antibody discovery. Because the process does not require a pre-defined, purified antigen, it can identify antibodies against novel, unknown cell surface markers that are unique to a specific disease state or tissue. The selected antibody can then be used as a tool to identify and characterize its previously unknown target, opening up entirely new avenues for therapeutic intervention.
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
